11 research outputs found

    Design and baseline characteristics of the finerenone in reducing cardiovascular mortality and morbidity in diabetic kidney disease trial

    Get PDF
    Background: Among people with diabetes, those with kidney disease have exceptionally high rates of cardiovascular (CV) morbidity and mortality and progression of their underlying kidney disease. Finerenone is a novel, nonsteroidal, selective mineralocorticoid receptor antagonist that has shown to reduce albuminuria in type 2 diabetes (T2D) patients with chronic kidney disease (CKD) while revealing only a low risk of hyperkalemia. However, the effect of finerenone on CV and renal outcomes has not yet been investigated in long-term trials. Patients and Methods: The Finerenone in Reducing CV Mortality and Morbidity in Diabetic Kidney Disease (FIGARO-DKD) trial aims to assess the efficacy and safety of finerenone compared to placebo at reducing clinically important CV and renal outcomes in T2D patients with CKD. FIGARO-DKD is a randomized, double-blind, placebo-controlled, parallel-group, event-driven trial running in 47 countries with an expected duration of approximately 6 years. FIGARO-DKD randomized 7,437 patients with an estimated glomerular filtration rate >= 25 mL/min/1.73 m(2) and albuminuria (urinary albumin-to-creatinine ratio >= 30 to <= 5,000 mg/g). The study has at least 90% power to detect a 20% reduction in the risk of the primary outcome (overall two-sided significance level alpha = 0.05), the composite of time to first occurrence of CV death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure. Conclusions: FIGARO-DKD will determine whether an optimally treated cohort of T2D patients with CKD at high risk of CV and renal events will experience cardiorenal benefits with the addition of finerenone to their treatment regimen. Trial Registration: EudraCT number: 2015-000950-39; ClinicalTrials.gov identifier: NCT02545049

    Wireless Optogenetic Stimulation of Oxytocin Neurons in a Semi-natural Setup Dynamically Elevates Both Pro-social and Agonistic Behaviors

    No full text
    Complex behavioral phenotyping techniques are becoming more prevalent in the field of behavioral neuroscience, and thus methods for manipulating neuronal activity must be adapted to fit into such paradigms. Here, we present a head-mounted, magnetically activated device for wireless optogenetic manipulation that is compact, simple to construct, and suitable for use in group-living mice in an enriched semi-natural arena over several days. Using this device, we demonstrate that repeated activation of oxytocin neurons in male mice can have different effects on pro-social and agonistic behaviors, depending on the social context. Our findings support the social salience hypothesis of oxytocin and emphasize the importance of the environment in the study of social neuromodulators. Our wireless optogenetic device can be easily adapted for use in a variety of behavioral paradigms, which are normally hindered by tethered light delivery or a limited environment

    Additional file 7: of A new role of hindbrain boundaries as pools of neural stem/progenitor cells regulated by Sox2

    No full text
    Expression of neural-differentiation markers in the hindbrain. A. (a) Representative flow cytometry plot from 18 HH hindbrain stained with Sox2 and Tuj1. Quantification of relative abundance of Sox2/Tuj1-expressing cells is shown. (b) Graphic representation of Sox2/Tuj1 distribution as percentage of total stained cells. B. Representative flat-mounted views of 15HH and 18HH hindbrains in situ hybridized with RNA probes against NeuroD, NSCL1 and Brn3a, or immunostained for HuC/D (n = 10/marker) (e-h). Expression of NSCL1 and HuC/D shifts from punctuated rhombomeric expression in 15HH to boundary-enhanced expression at 18HH. C. (a-c) Representative flat-mounted views of 18HH hindbrains stained for Sox2 and HuC/D (n = 10). Merged image is shown in (c). (d-g) Sequential Z-stack analysis from 0 to –20 μm of a boundary area. Arrows indicate site of neural differentiation. Scale bars = 100 μm. D. Scheme of the clonal-analysis of HB cell-labeling experiment using injection of AFP plasmid into single cells and harvesting at two time points. (TIF 4496 kb

    Additional file 6: of A new role of hindbrain boundaries as pools of neural stem/progenitor cells regulated by Sox2

    No full text
    CM-DiI labeling of boundary and rhombomere cells. Representative flat-mount confocal views of CM-DiI labelled rhombomere (a,b) or boundary (c,d) (n = 5 hindbrains). Arrows indicate injection site, yellow lines indicate boundaries. Outlined areas in (b,d) show dye expansion. (TIF 11336 kb
    corecore